|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Digital array for biomarker discovery. |
|
| Management |
| Gitte L. Pedersen, CEO, Co-Founder; Jesper Zeuthen, D.Sc., President; Morten L. Pedersen, CTO, founder; Jan Lomholdt, CBO tools; Paul Rohricht, CBO diagnostics; |
| |
|
|
| |
|
| Keywords |
| genomics, digital array, DNA barcode, Denmark, discovery tools, genome, detection tools, diagnostics, gene chip, gene array, next generation sequencing.Allergy, Cardiology, Dermatology, Diabetes, Diagnostics, Gastroenterology, HIVAIDS, Immunology, Infectious Disease, Neurology, Obesity, Oncology, PatientMonitoring, Software Systems, WoundCare,
Healthcare IT |
|
|
|
| Description |
|
Genomic Expression develops proprietary cost-effective genomics diagnostics tools for personalized medicine in order to increase the effectiveness of research and delivery of healthcare. The Company’s genomic signatures translate into easily-understood information on treatment options. Genomic’s technology is based on an intelligent target filtering technology that is integrated with detection of short reads on a small chip, can turn an existing array infrastructure into a sequencing infrastructure, and can be applied as sample preparation/application engine for sequencing platforms. It can also be used to analyze nucleic acids from any possible source, allowing for a wide range of applications ranging from digital gene expression to profiling of mixtures of unknown organisms, and can even be used as a closed platform to detect known signals. This technology leads the standard away from guessing or limiting a given project to known markers and to entering directly into the clinic, where new markers can be discovered in the process, increasing the probability of success. This earlier-stage clinical company’s platform reduces the amount of data processing involved while barring loss of information, allowing savings of up to two years in pre-clinic and up to $20M. |
|
| Products / Services |
Genomic Expression is launching a first generation digital array to key universities and corporations. In addition to this the company is exploring various deal opportunities including:
1) Applying the DNA barcode technology as an application platform for next generation sequencing.
2) Service provider for discovery of biomarkers and development of companion diagnostics for drug discovery companies.
3) Access to the DATATM platform for specific applications and therapeutic/geographic areas.
4) Joint Venture developing a digital array for sequencing utilizing the DNA Barcode technology with current gene chip provider.
5) Access to the DNA Barcode technology on a specific diagnostic platform.
|
|
| Technology / Differentiation |
| Genomic Expression's DATA platform enjoys a cost and performance advantage over current gene arrays. DATA abbreviates the process of developing diagnostics for Personalized Medicine, because it can be directly applied in the biomarker discovery process without a priori assumptions regarding what markers to look for, and the same product can evolve into a companion diagnostic without any further laboratory development. |
|
| Market / Customers |
Genomic Expression has initiated projects with strategic partners such as New York University, Columbia University, The National Cancer Institute, Harvard Partners, The John F. Kennedy Institute, Copenhagen University and The Danish Cancer Society. All these partners turn into customers upon successful completion, and the projects themselves turn into additional product opportunities for specific applications. The genomic research market is presently $2 billion. Key players are Affymetrix, Illumina, Agilent, Nimblegen and Life Technologies. The molecular diagnostic market is now $3 billion and is expected to grow to $7 billion in 2015 (PWC). There are significant markets outside the medical field in industrial applications as well as in wellness and cosmetics.
|
|
| Competitors / Substitutes / Alternatives |
Largest genomic tool provides include: Affymetrix, Illumina, Agilent, Nimblegen/Roche and Life Technologies. Largest genomics pronostic/diagnostic providers include: Genomic Health, Myriad, Gen- Probe.
|
|
| Strategy |
It is Genomic Expressions exit strategy to get acquired. Any of the current array providers; Affymetrix, Agilent or Nimblegen/Roche are very likely exit opportunities, in addition to all the other genomic tools & diagnostic companies, however the exit landscape has dramatically expanded to include traditional diagnostic companies (Labcorp acquired Monogram, Quest has invested in Somalogic and Abbott acquired Ibis) and technology companies interested in the genomic space (Google has invested in 23andme, Intel in Pacific Bioscience and Microsoft acquired Rosetta Bioinformatics).
|
|
| Funding |
| Genomic Expression is raising $1 mill now to market out first generation digital array, advance our IP, prepare for production, for a series A/and or exit. |
|
| Status |
| First generation products are commercially and ready to launch. The technology can be further scaled to enable the interrogation of larger genomes and additional applications and Genomic Expression has invented a second generation platform that will drive cost down even further. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members